IN2014DN03049A - - Google Patents

Info

Publication number
IN2014DN03049A
IN2014DN03049A IN3049DEN2014A IN2014DN03049A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A IN 3049DEN2014 A IN3049DEN2014 A IN 3049DEN2014A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A
Authority
IN
India
Prior art keywords
extracellular matrix
tissue
interstitial
expression
ecm
Prior art date
Application number
Other languages
English (en)
Inventor
Allison A Eddy
Daryl M Okamura
Original Assignee
Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Res Inst filed Critical Seattle Childrens Res Inst
Publication of IN2014DN03049A publication Critical patent/IN2014DN03049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3049DEN2014 2011-10-26 2011-10-26 IN2014DN03049A (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
IN2014DN03049A true IN2014DN03049A (OSRAM) 2015-05-15

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3049DEN2014 IN2014DN03049A (OSRAM) 2011-10-26 2011-10-26

Country Status (7)

Country Link
US (2) US9468612B2 (OSRAM)
AU (1) AU2011379972B2 (OSRAM)
BR (1) BR112014009789A2 (OSRAM)
CA (1) CA2853484C (OSRAM)
IN (1) IN2014DN03049A (OSRAM)
MX (1) MX2014004994A (OSRAM)
WO (1) WO2013062544A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028448A2 (pt) * 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos
JP7418958B2 (ja) * 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
WO2018148254A1 (en) * 2017-02-07 2018-08-16 Children's Hospital Medical Center Treatment of asthma with cysteamine
EP4534527A3 (en) 2017-09-20 2025-06-18 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019094862A1 (en) * 2017-11-10 2019-05-16 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
WO2020210218A1 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Methods for treating inherited eye defects
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE154514T1 (de) 1989-09-29 1997-07-15 Jolla Cancer Res Found Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix
JPH05503003A (ja) 1989-11-22 1993-05-27 ジェネンテク，インコーポレイテッド 潜在性関与ペプチドおよびその使用
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ATE233568T1 (de) 1991-11-14 2003-03-15 Jolla Cancer Res Found Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
ATE211762T1 (de) 1993-04-30 2002-01-15 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU2749697A (en) 1996-04-30 1997-11-19 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
ES2253788T3 (es) 1996-10-25 2006-06-01 Ethicon, Inc. Ensayo de agente anti-fibrotico.
EE9900492A (et) 1997-04-18 2000-06-15 Biogen, Incorporated II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
ES2237671T3 (es) 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003224335A1 (en) 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
WO2004010929A2 (en) 2002-07-25 2004-02-05 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US20040132730A1 (en) 2002-09-10 2004-07-08 Jonathan Axon Inhibitors of TGFbeta
US7365066B2 (en) 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
AU2003291642A1 (en) 2002-11-22 2004-06-18 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US20040127575A1 (en) 2002-11-22 2004-07-01 Feng Ying Method for counteracting a pathologic change in the beta-adrenergic pathway
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004050659A1 (en) 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
US20040192583A1 (en) 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2004087056A2 (en) 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20050245508A1 (en) 2003-12-24 2005-11-03 Scios, Inc. Treatment of malignant gliomas with TGF-beta inhibitors
WO2005092894A1 (en) 2004-03-01 2005-10-06 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
EP1786802A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006026305A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
PL1850873T3 (pl) 2005-02-08 2019-06-28 Genzyme Corporation Przeciwciała przeciwko tgfbeta
DK1919458T6 (en) 2006-01-27 2017-03-27 Univ California Acid-resistant coated cysteamine, cystamine and derivatives thereof
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
EP2636404B1 (en) * 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products

Also Published As

Publication number Publication date
BR112014009789A2 (pt) 2017-04-25
US9925154B2 (en) 2018-03-27
CA2853484A1 (en) 2013-05-02
WO2013062544A1 (en) 2013-05-02
US20140275279A1 (en) 2014-09-18
AU2011379972A1 (en) 2014-05-15
CA2853484C (en) 2018-08-21
US9468612B2 (en) 2016-10-18
US20170165207A1 (en) 2017-06-15
MX2014004994A (es) 2014-08-27
AU2011379972B2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
IN2014DN03049A (OSRAM)
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
BR112013029800A2 (pt) tratamento de degeneração do disco intervertebral com o uso de células derivadas do tecido do tecido do cordão umbilical humano
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
PT3087178T (pt) Método para produzir oxalato oxidases que têm atividade ótica próxima ao ph fisiológico e utilização de tais oxalato oxidases recombinantes no tratamento de doenças relacionadas com oxalato
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
HRP20150117T1 (xx) Pripravci kolagenaze g i kolagenaze h za lijeäśenje bolesti koje ukljuäśuju promjene kolagena
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
ZA201302638B (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
NZ595440A (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
IL215406A0 (en) Electromedical device for the non-invasive reduction or removal of subcutaneous adipose tissue
GB201018154D0 (en) Method of treatment
AU336535S (en) Medical dressing
AU336536S (en) Medical dressing
ZA201005770B (en) The treatment of damaged skin
UA44660U (ru) Способ лечения больных системными заболеваниями соединительной ткани с преимущественным поражением кожи
AU2010905197A0 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
UA99774C2 (ru) Лечение воспалительных заболеваний бета-дефензинами млекопитающих
UA65158U (ru) Способ лечения трофических язв нижних конечностей
AU2013900043A0 (en) Continuous non-invasive optical measurement of tissue oxygen delivery